Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanfor... Read more
Sutro Biopharma
3 followers
Active Motif
3 followers
Dyno Therapeutics
4 followers
Janux Therapeutics
1 follower
Eikon Therapeutics
3 followers
Gilead Sciences
161 followers
Regeneron
132 followers
Illumina
79 followers
Agilent Technologies
82 followers
Verily Life Sciences
45 followers
Alexion Pharmaceuticals
45 followers
Explore companies